Ascendis Pharma FY Conference Summary Company Overview - **Company**: Ascendis Pharma (NasdaqGS:ASND) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points Product Launch and Approval - Ascendis Pharma received approval for **UVEVELL**, a new treatment for hypoparathyroidism, with a clean label and minimal adverse events [3][4] - The drug is designed for weekly administration and can be stored at room temperature for up to 6 months, differentiating it from competitors like **VOXZOGO** [3] - The launch is expected in early Q2 2026, pending final packaging information from the FDA [4] Market Potential - There are approximately **2,600 patients** diagnosed with hypoparathyroidism in the U.S., with only **30%** currently receiving treatment [4][8] - Ascendis aims to target both existing patients on other therapies and new patients who are currently untreated [9][10] - The company believes that a significant portion of patients will switch to **YORVIPATH** due to its benefits over existing treatments [9][10] Competitive Landscape - **VOXZOGO** has a known risk of blood pressure changes requiring hydration, while **YORVIPATH** does not have such stringent requirements, which may enhance its appeal [12][13] - Ascendis plans to price **YORVIPATH** at a premium, reflecting its superior benefits, but will also consider contracting with payers to maximize access [19][20] Patient Engagement and Market Penetration - Ascendis emphasizes a patient-focused approach, engaging with patient groups to understand their needs and improve treatment uptake [29][30] - The company believes that addressing comorbidities will drive treatment rates, with expectations that **70-80%** of patients will eventually seek treatment [33][34] Future Developments - Ascendis is also exploring a once-weekly version of **YORVIPATH**, which may require a different regulatory pathway for approval [44][45] - The company is focused on ensuring optimal patient journeys and minimizing dropouts during the treatment initiation phase [42][43] Financial Considerations - The company anticipates that the pricing strategy and patient support systems will help maintain demand and manage gross-to-net revenue dynamics [35][37] Conclusion - Ascendis Pharma is positioned to capitalize on the unmet needs in the hypoparathyroidism market with its innovative treatment **YORVIPATH**, leveraging its patient-centric approach and strategic pricing to enhance market penetration and patient outcomes [20][29][33]

Core Insights - The core viewpoint of the article is that Weisheng Pharmaceutical's innovative product, Weizhen Gao® (long-acting growth hormone), has received approval from the National Medical Products Administration, marking a significant milestone in the growth hormone market due to its unique technology and clinical advantages [1][2]. Product Core: Building a Differentiated Moat - Weizhen Gao® is the first long-acting growth hormone that maintains the natural structure of the active molecule, overcoming a significant industry technical barrier [2]. - The product utilizes a unique "TransCon" technology platform that allows for the temporary connection of the growth hormone with an inert carrier, enabling a controlled release of the active ingredient [2][3]. - Clinical studies have shown that Weizhen Gao® has superior efficacy compared to daily administration growth hormones, with significant improvements in annualized growth rate (AHV) and height standard deviation score (SDS) [3][4]. Market Strategy: Differentiated Commercial Pathway - The pricing strategy for Weizhen Gao® will reflect its unique attributes, with an expected annual treatment cost significantly higher than other long-acting growth hormones, justified by its clinical and technical advantages [7][8]. - Weisheng Pharmaceutical has adopted a "light asset, heavy cooperation" approach for market expansion, partnering with established companies for distribution and promotion [8][9]. - The company aims to establish a comprehensive "screening-diagnosis-management" process through collaborations with high-end private hospitals [9]. Team Building: High Standards for Execution - The company emphasizes a rigorous recruitment and training process for its commercial team, ensuring a high level of expertise and industry experience [10]. - A strict assessment mechanism is in place to maintain high standards of knowledge and performance among team members [10]. Long-term Outlook: From Single Product to Platform Value - The approval of Weizhen Gao® paves the way for future products under the TransCon technology platform, with significant sales potential anticipated for upcoming products targeting various endocrine disorders [14]. - The company aims to establish itself as a leading player in the endocrine and metabolic field, with a long-term goal of becoming a billion-dollar innovative pharmaceutical enterprise [14].